INMB INmune Bio: Company Value to Revenue Ratio

inmunebio.com (INMB) - corporate logo

The development of INmune Bio, Inc. (INMB) is based on scientific progress in immune modulation, rendering the business independent of economic cycles. The current EV/Sales ratio demonstrates the asset's value dynamics, while 0.00 shows the value of this parameter. Alzheimer's disease therapy possesses high macro-resilience and stable demand. However, the company's success relies entirely on clinical trial results and strict control of R&D expenses.

INmune Bio Corp (INMB) Company Value to Revenue: for the period 11/23/2025 - 11/20/2026

inmunebio.com - analytical breakdowns and key metrics (INMB)

- market price and analyst price targets:
Fundamental valuation:INmune Bio, Inc. INMB
Finished products of INmune Bio, Inc.

The lack of stable cash flows due to the clinical status of INmune Bio (INMB) developments makes traditional revenue analysis difficult. The Enterprise Value-to-Sales (EV/Sales) ratio allows for an assessment of market expectations regarding fundamental indicators; therefore, monitoring the business valuation level via EV/Sales helps distinguish long-term trends from short-term speculative momentum, minimizing emotional risks when investing.

Competitor analysis for INmune Bio, Inc.

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Aurinia Pharma AUPH|biocryst.com (BCRX) - Enterprise Value-to-Revenue Ratio|Vera Therapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Dianthus Therapeutics Inc|Pharvaris NV (PHVS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple ABCL|Tourmaline Corp - Company Value to Revenue Ratio|EV/Sales Multiple PGEN (precigen.com)|Enterprise Value-to-Sales Ratio pharming.com|NKTR - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Upstream Bio Corp|ZBIO: EV/Sales Multiple|Company Value to Revenue Immunome, Inc.|Company Value to Revenue GOSS|KALV: Business Value to Revenue|EV/Sales Multiple SEPN|Company Value to Revenue Pieris Pharmaceuticals, Inc. PVLA|EV/Sales Multiple SVRA (Savara Inc)|EV/Sales Multiple Rigel Pharmaceuticals RIGL|AnaptysBio Inc. - EV/Sales Multiple|Astria Therapeutics - Enterprise Value-to-Revenue Coefficient|ENGN: EV/Sales Multiple|RAPT - Total Company Value-to-Revenue Ratio|Company Value to Revenue JBIO|Aclaris (ACRS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple KYTX|Company Value to Revenue Tiziana Life Sciences TLSA|EV/Sales Multiple CABA (cabalettabio.com)|Enterprise Value-to-Revenue Coefficient VTYX (Ventyx Bio)|Theratechnologies, Inc - EV/Sales Multiple|AVTX (Avalo Therapeutics Inc.) - Company Value to Revenue Ratio|eledon.com (ELDN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio AGEN|CLYM (climbbio.com) - EV/Sales Multiple|EV/Sales Multiple zurabio.com|Enterprise Value-to-Revenue Ratio aTyr (ATYR)|ADAG - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio ImageneBio Inc IMA|EV/Sales Multiple Shattuck Labs, Inc. STTK|EQ - Enterprise Value-to-Revenue Ratio|connectbiopharm.com (CNTB) - Company Value to Revenue|IMUX (Immunic) - Company Value to Revenue|Atara Biotherapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio InflaRx|Company Value to Revenue x4pharma.com (XFOR)|EV/Sales Multiple ACET|Company Value to Revenue Celularity Corp CELU|Enterprise Value-to-Revenue Ratio Barinthus Biotherapeutics plc BRNS|KZR - Company Value to Revenue|sabbiotherapeutics.com - EV/Sales Multiple|akaritx.com (AKTX) - Company Value to Revenue|ENLV: EV/Sales Multiple|QTTB (Q32 Bio Inc) - Enterprise Value-to-Revenue Ratio|GOVX (geovax.com) - EV/Sales Multiple|EV/Sales Multiple Edesa Biotech Corp|EV/Sales Multiple IBIO|Company Value to Revenue Carisma Tx CARM|Enterprise Value-to-Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|EV/Sales Multiple Bolt Biotherapeutics BOLT|HCW Biologics - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple aptevotherapeutics.com|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD